In a report issued on May 1, Marc Goodman from SVB Securities maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN – Research Report). The company’s shares closed last Tuesday at $90.10.
According to TipRanks.com, Goodman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.4% and a 41.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Amylyx Pharmaceuticals Inc, and Intra-Cellular Therapies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biohaven Pharmaceutical Holding Co with a $157.50 average price target, a 69.0% upside from current levels. In a report issued on May 2, Piper Sandler also maintained a Buy rating on the stock with a $170.00 price target.
Biohaven Pharmaceutical Holding Co’s market cap is currently $6.35B and has a P/E ratio of -6.85.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.
Read More on BHVN: